Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where James A. Bankson is active.

Publication


Featured researches published by James A. Bankson.


Nature Medicine | 2006

Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma

Premal H. Thaker; Liz Y. Han; Aparna A. Kamat; Jesusa M.G. Arevalo; Rie Takahashi; Chunhua Lu; Nicholas B. Jennings; Guillermo N. Armaiz-Pena; James A. Bankson; Murali Ravoori; William M. Merritt; Yvonne G. Lin; Lingegowda S. Mangala; Tae Jin Kim; Robert L. Coleman; Charles N. Landen; Yang Li; Edward Felix; Angela Sanguino; Robert A. Newman; Mary Lloyd; David M. Gershenson; Vikas Kundra; Gabriel Lopez-Berestein; Susan K. Lutgendorf; Steven W. Cole; Anil K. Sood

Stress can alter immunological, neurochemical and endocrinological functions, but its role in cancer progression is not well understood. Here, we show that chronic behavioral stress results in higher levels of tissue catecholamines, greater tumor burden and more invasive growth of ovarian carcinoma cells in an orthotopic mouse model. These effects are mediated primarily through activation of the tumor cell cyclic AMP (cAMP)–protein kinase A (PKA) signaling pathway by the β2 adrenergic receptor (encoded by ADRB2). Tumors in stressed animals showed markedly increased vascularization and enhanced expression of VEGF, MMP2 and MMP9, and we found that angiogenic processes mediated the effects of stress on tumor growth in vivo. These data identify β-adrenergic activation of the cAMP–PKA signaling pathway as a major mechanism by which behavioral stress can enhance tumor angiogenesis in vivo and thereby promote malignant cell growth. These data also suggest that blocking ADRB-mediated angiogenesis could have therapeutic implications for the management of ovarian cancer.


Nature Nanotechnology | 2010

Three-dimensional tissue culture based on magnetic cell levitation

Glauco R. Souza; Jennifer R. Molina; Robert M. Raphael; Michael G. Ozawa; Daniel Stark; Carly S. Levin; Lawrence Bronk; Jeyarama S. Ananta; Jami Mandelin; Maria-Magdalena Georgescu; James A. Bankson; Juri G. Gelovani; T. C. Killian; Wadih Arap; Renata Pasqualini

Cell culture is an essential tool in drug discovery, tissue engineering and stem cell research. Conventional tissue culture produces two-dimensional cell growth with gene expression, signalling and morphology that can be different from those found in vivo, and this compromises its clinical relevance. Here, we report a three-dimensional tissue culture based on magnetic levitation of cells in the presence of a hydrogel consisting of gold, magnetic iron oxide nanoparticles and filamentous bacteriophage. By spatially controlling the magnetic field, the geometry of the cell mass can be manipulated, and multicellular clustering of different cell types in co-culture can be achieved. Magnetically levitated human glioblastoma cells showed similar protein expression profiles to those observed in human tumour xenografts. Taken together, these results indicate that levitated three-dimensional culture with magnetized phage-based hydrogels more closely recapitulates in vivo protein expression and may be more feasible for long-term multicellular studies.


European Heart Journal | 2010

Both cultured and freshly isolated adipose tissue-derived stem cells enhance cardiac function after acute myocardial infarction

Xiaowen Bai; Yasheng Yan; Yao-Hua Song; Max Seidensticker; Brian Rabinovich; Roxana Metzele; James A. Bankson; Daynene M. Vykoukal; Eckhard Alt

AIMS We assessed whether freshly isolated human adipose tissue-derived cells (fhADCs) or cultured human adipose tissue-derived stem cells (hASCs) have beneficial effects on cardiac function after myocardial infarction (MI), whether the injected cells can survive long term, and whether their effects result from direct differentiation or paracrine mechanisms. METHODS AND RESULTS Myocardial infarction was experimentally induced in severe combined immunodeficient mice, and either fhADCs, cultured hASCs, or phosphate-buffered saline was injected into the peri-infarct region. Myocardial function improved significantly in mice treated with hASCs or fhADCs 4 weeks after MI. Immunofluorescence revealed that grafted hASCs and fhADCs underwent cardiomyogenic differentiation pathway, as indicated by expression of connexin 43 and troponin I in a fusion-independent manner. Some of the injected cells integrated with host cardiomyocytes through connexin 43, and others were incorporated into newly formed vessels. Human adipose tissue-derived stem cells survived in injured hearts up to 4 months, as detected by luciferase-based bioluminescence imaging. Vascular density was significantly increased, and fewer apoptotic cells were present in the peri-infarct region of cell-injected mice. CONCLUSION This is the first study to systematically compare the effects of fhADCs and hASCs on myocardial regeneration. Both cell types engraft into infarcted myocardium, survive, and improve myocardial function, suggesting that fhADCs, like hASCs, are a promising alternative cell source for myocardial repair after MI.


Journal of Clinical Investigation | 2007

An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic

Ariel Fernández; Angela Sanguino; Zhenghong Peng; Eylem Ozturk; Jianping Chen; Alejandro Crespo; Sarah Wulf; Aleksander Shavrin; Chaoping Qin; Jianpeng Ma; Jonathan C. Trent; Yvonne G. Lin; Hee Dong Han; Lingegowda S. Mangala; James A. Bankson; Juri G. Gelovani; Allen M. Samarel; William G. Bornmann; Anil K. Sood; Gabriel Lopez-Berestein

Targeting kinases is central to drug-based cancer therapy but remains challenging because the drugs often lack specificity, which may cause toxic side effects. Modulating side effects is difficult because kinases are evolutionarily and hence structurally related. The lack of specificity of the anticancer drug imatinib enables it to be used to treat chronic myeloid leukemia, where its target is the Bcr-Abl kinase, as well as a proportion of gastrointestinal stromal tumors (GISTs), where its target is the C-Kit kinase. However, imatinib also has cardiotoxic effects traceable to its impact on the C-Abl kinase. Motivated by this finding, we made a modification to imatinib that hampers Bcr-Abl inhibition; refocuses the impact on the C-Kit kinase; and promotes inhibition of an additional target, JNK, a change that is required to reinforce prevention of cardiotoxicity. We established the molecular blueprint for target discrimination in vitro using spectrophotometric and colorimetric assays and through a phage-displayed kinase screening library. We demonstrated controlled inhibitory impact on C-Kit kinase in human cell lines and established the therapeutic impact of the engineered compound in a novel GIST mouse model, revealing a marked reduction of cardiotoxicity. These findings identify the reengineered imatinib as an agent to treat GISTs with curbed side effects and reveal a bottom-up approach to control drug specificity.


Journal of Clinical Investigation | 2010

Cardiomyocyte PDGFR-β signaling is an essential component of the mouse cardiac response to load-induced stress

Vishnu Chintalgattu; Di Ai; Robert R. Langley; Jianhu Zhang; James A. Bankson; Tiffany Shih; Anilkumar K. Reddy; Kevin R. Coombes; Iyad N. Daher; Shibani Pati; Shalin S. Patel; Jennifer S. Pocius; George E. Taffet; L. Maximillian Buja; Mark L. Entman; Aarif Y. Khakoo

PDGFR is an important target for novel anticancer therapeutics because it is overexpressed in a wide variety of malignancies. Recently, however, several anticancer drugs that inhibit PDGFR signaling have been associated with clinical heart failure. Understanding this effect of PDGFR inhibitors has been difficult because the role of PDGFR signaling in the heart remains largely unexplored. As described herein, we have found that PDGFR-beta expression and activation increase dramatically in the hearts of mice exposed to load-induced cardiac stress. In mice in which Pdgfrb was knocked out in the heart in development or in adulthood, exposure to load-induced stress resulted in cardiac dysfunction and heart failure. Mechanistically, we showed that cardiomyocyte PDGFR-beta signaling plays a vital role in stress-induced cardiac angiogenesis. Specifically, we demonstrated that cardiomyocyte PDGFR-beta was an essential upstream regulator of the stress-induced paracrine angiogenic capacity (the angiogenic potential) of cardiomyocytes. These results demonstrate that cardiomyocyte PDGFR-beta is a regulator of the compensatory cardiac response to pressure overload-induced stress. Furthermore, our findings may provide insights into the mechanism of cardiotoxicity due to anticancer PDGFR inhibitors.


Science Translational Medicine | 2013

Coronary Microvascular Pericytes Are the Cellular Target of Sunitinib Malate–Induced Cardiotoxicity

Vishnu Chintalgattu; Meredith L. Rees; James C. Culver; Aditya Goel; Tilahu Jiffar; Jianhu Zhang; Kenneth Dunner; Shibani Pati; James A. Bankson; Renata Pasqualini; Wadih Arap; Nathan S. Bryan; Heinrich Taegtmeyer; Robert R. Langley; Hui Yao; Michael E. Kupferman; Mark L. Entman; Mary E. Dickinson; Aarif Y. Khakoo

Sunitinib-induced cardiotoxicity is caused by depletion of coronary pericytes due to loss of PDGFR signaling; this side effect can be prevented by thalidomide. Saving Pericytes to Prevent a Broken Heart In the world of targeted cancer therapies, sunitinib is a versatile one, targeting a variety of tyrosine kinase receptors. The breadth of its activity allows it to be effective in multiple different types of cancer but also increases the chances of unintended adverse effects. One such side effect is cardiotoxicity, with frequent reports of left ventricular dysfunction and heart failure in patients treated with sunitinib. Chintalgattu and co-workers have now uncovered the mechanism for this toxicity and demonstrated a way to protect the heart from treatment-induced damage in a mouse model. Pericytes are contractile cells that wrap around small blood vessels and are essential to their function. After sunitinib treatment, pericytes were no longer coating the coronary microvasculature in a mouse model. The blood vessels depleted of pericytes were unusually leaky, and the hearts of treated animals showed clear evidence of cardiac dysfunction. The depletion of pericytes was caused by the inhibition of signaling through platelet-derived growth factor receptor (PDGFR), a known target of sunitinib. The authors also discovered that thalidomide, a small-molecule drug that is already used in humans for the treatment of some cancers, could protect pericytes and prevent sunitinib-induced cardiotoxicity without affecting the antitumor effects of sunitinib. Future studies will be needed to uncover additional mechanism explaining why coronary pericytes in particular are so sensitive to inhibition of PDGFR and how thalidomide can protect these cells from toxicity. Eventually, this research could enable the creation of more specific targeted drugs that inhibit the kinases driving cancer cell proliferation without injuring pericytes and other healthy cells. In the meantime, the current findings of Chintalgattu et al. provide a rationale for testing the combination of thalidomide and sunitinib in human cancer patients to protect the patients’ hearts from injury while continuing to effectively target cancer cells. Sunitinib malate is a multitargeted receptor tyrosine kinase inhibitor used in the treatment of human malignancies. A substantial number of sunitinib-treated patients develop cardiac dysfunction, but the mechanism of sunitinib-induced cardiotoxicity is poorly understood. We show that mice treated with sunitinib develop cardiac and coronary microvascular dysfunction and exhibit an impaired cardiac response to stress. The physiological changes caused by treatment with sunitinib are accompanied by a substantial depletion of coronary microvascular pericytes. Pericytes are a cell type that is dependent on intact platelet-derived growth factor receptor (PDGFR) signaling but whose role in the heart is poorly defined. Sunitinib-induced pericyte depletion and coronary microvascular dysfunction are recapitulated by CP-673451, a structurally distinct PDGFR inhibitor, confirming the role of PDGFR in pericyte survival. Thalidomide, an anticancer agent that is known to exert beneficial effects on pericyte survival and function, prevents sunitinib-induced pericyte cell death in vitro and prevents sunitinib-induced cardiotoxicity in vivo in a mouse model. Our findings suggest that pericytes are the primary cellular target of sunitinib-induced cardiotoxicity and reveal the pericyte as a cell type of concern in the regulation of coronary microvascular function. Furthermore, our data provide preliminary evidence that thalidomide may prevent cardiotoxicity in sunitinib-treated cancer patients.


Circulation Research | 2010

Human CD34+ Cells in Experimental Myocardial Infarction. Long-Term Survival, Sustained Functional Improvement, and Mechanism of Action

Jingxiong Wang; Sui Zhang; Brian Rabinovich; Luc Bidaut; Suren Soghomonyan; Mian M. Alauddin; James A. Bankson; Elizabeth J. Shpall; James T. Willerson; Juri G. Gelovani; Edward T.H. Yeh

Rationale: Human CD34+ cells have been used in clinical trials for treatment of myocardial infarction (MI). However, it is unknown how long the CD34+ cells persist in hearts, whether the improvement in cardiac function is sustained, or what are the underlying mechanisms. Objective: We sought to track the fate of injected human CD34+ cells in the hearts of severe combined immune deficiency (SCID) mice after experimental MI and to determine the mechanisms of action. Methods and Results: We used multimodality molecular imaging to track the fate of injected human CD34+ cells in the hearts of SCID mice after experimental MI, and used selective antibody blocking to determine the mechanisms of action. Bioluminescence imaging showed that injected CD34+ cells survived in the hearts for longer than 12 months. The PET signal from the injected cells was detected in the wall of the left ventricle. Cardiac MRI showed that left ventricular ejection fraction was significantly improved in the treated mice compared to the control mice for up to 52 weeks (P<0.05). Furthermore, treatment with anti-&agr;4&bgr;1 showed that generation of human-derived cardiomyocytes was inhibited, whereas anti–vascular endothelial growth factor (VEGF) treatment blocked the production of human-derived endothelial cells. However, the improvement in cardiac function was abolished only in the anti-VEGF, but not anti-&agr;4&bgr;1, treated group. Conclusions: Angiogenesis and/or paracrine effect, but not myogenesis, is responsible for functional improvement following CD34+ cells therapy.


Small | 2010

Cellular Association and Assembly of a Multistage Delivery System

Rita E. Serda; Aaron Mack; Merlyn Pulikkathara; Ana Maria Zaske; Ciro Chiappini; Jean R. Fakhoury; Douglas Webb; Biana Godin; Jodie L. Conyers; Xue W. Liu; James A. Bankson; Mauro Ferrari

The realization that blood-borne delivery systems must overcome a multiplicity of biological barriers has led to the fabrication of a multistage delivery system (MDS) designed to temporally release successive stages of particles or agents to conquer sequential barriers, with the goal of enhancing delivery of therapeutic and diagnostic agents to the target site. In its simplest form, the MDS comprises stage-one porous silicon microparticles that function as carriers of second-stage nanoparticles. Cellular uptake of nontargeted discoidal silicon microparticles by macrophages is confirmed by electron and atomic force microscopy (AFM). Using superparamagnetic iron oxide nanoparticles (SPIONs) as a model of secondary nanoparticles, successful loading of the porous matrix of silicon microparticles is achieved, and retention of the nanoparticles is enhanced by aminosilylation of the loaded microparticles with 3-aminopropyltriethoxysilane. The impact of silane concentration and reaction time on the nature of the silane polymer on porous silicon is investigated by AFM and X-ray photoelectron microscopy. Tissue samples from mice intravenously administered the MDS support co-localization of silicon microparticles and SPIONs across various tissues with enhanced SPION release in spleen, compared to liver and lungs, and enhanced retention of SPIONs following silane capping of the MDS. Phantom models of the SPION-loaded MDS display negative contrast in magnetic resonance images. In addition to forming a cap over the silicon pores, the silane polymer provides free amines for antibody conjugation to the microparticles, with both VEGFR-2- and PECAM-specific antibodies leading to enhanced endothelial association. This study demonstrates the assembly and cellular association of a multiparticle delivery system that is biomolecularly targeted and has potential for applications in biological imaging.


Neuro-oncology | 2010

Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma

Dimpy Koul; Ruijun Shen; Yong Wan Kim; Yasuko Kondo; Yiling Lu; James A. Bankson; Sabrina M. Ronen; D. Lynn Kirkpatrick; Garth Powis; W. K. Alfred Yung

The phosphatidylinositol-3-kinase (PI3K)/Akt oncogenic pathway is critical in glioblastomas. Loss of PTEN, a negative regulator of the PI3K pathway or activated PI3K/Akt pathway that drive increased proliferation, survival, neovascularization, glycolysis, and invasion is found in 70%-80% of malignant gliomas. Thus, PI3K is an attractive therapeutic target for malignant glioma. We report that a new irreversible PI3K inhibitor, PX-866, shows potent inhibitory effects on the PI3K/Akt signaling pathway in glioblastoma. PX-866 did not induce any apoptosis in glioma cells; however, an increase in autophagy was observed. PX-866 inhibited the invasive and angiogenic capabilities of cultured glioblastoma cells. In vivo, PX-866 inhibited subcutaneous tumor growth and increased the median survival time of animals with intracranial tumors. We also assessed the potential of proton magnetic resonance spectroscopy (MRS) as a noninvasive method to monitor response to PX-866. Our findings show that PX-866 treatment causes a drop in the MRS-detectable choline-to-NAA, ratio and identify this partial normalization of the tumor metabolic profile as a biomarker of molecular drug action. Our studies affirm that the PI3K pathway is a highly specific molecular target for therapies for glioblastoma and other cancers with aberrant PI3K/PTEN expression.


PLOS ONE | 2009

New Dual Mode Gadolinium Nanoparticle Contrast Agent for Magnetic Resonance Imaging

Ketan B. Ghaghada; Murali Ravoori; Divya Sabapathy; James A. Bankson; Vikas Kundra; Ananth Annapragada

Background Liposomal-based gadolinium (Gd) nanoparticles have elicited significant interest for use as blood pool and molecular magnetic resonance imaging (MRI) contrast agents. Previous generations of liposomal MR agents contained gadolinium-chelates either within the interior of liposomes (core-encapsulated gadolinium liposomes) or presented on the surface of liposomes (surface-conjugated gadolinium liposomes). We hypothesized that a liposomal agent that contained both core-encapsulated gadolinium and surface-conjugated gadolinium, defined herein as dual-mode gadolinium (Dual-Gd) liposomes, would result in a significant improvement in nanoparticle-based T1 relaxivity over the previous generations of liposomal agents. In this study, we have developed and tested, both in vitro and in vivo, such a dual-mode liposomal-based gadolinium contrast agent. Methodology/Principal Findings Three types of liposomal agents were fabricated: core-encapsulated, surface-conjugated and dual-mode gadolinium liposomes. In vitro physico-chemical characterizations of the agents were performed to determine particle size and elemental composition. Gadolinium-based and nanoparticle-based T1 relaxivities of various agents were determined in bovine plasma. Subsequently, the agents were tested in vivo for contrast-enhanced magnetic resonance angiography (CE-MRA) studies. Characterization of the agents demonstrated the highest gadolinium atoms per nanoparticle for Dual-Gd liposomes. In vitro, surface-conjugated gadolinium liposomes demonstrated the highest T1 relaxivity on a gadolinium-basis. However, Dual-Gd liposomes demonstrated the highest T1 relaxivity on a nanoparticle-basis. In vivo, Dual-Gd liposomes resulted in the highest signal-to-noise ratio (SNR) and contrast-to-noise ratio in CE-MRA studies. Conclusions/Significance The dual-mode gadolinium liposomal contrast agent demonstrated higher particle-based T1 relaxivity, both in vitro and in vivo, compared to either the core-encapsulated or the surface-conjugated liposomal agent. The dual-mode gadolinium liposomes could enable reduced particle dose for use in CE-MRA and increased contrast sensitivity for use in molecular imaging.

Collaboration


Dive into the James A. Bankson's collaboration.

Top Co-Authors

Avatar

Stephen Y. Lai

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Marc S. Ramirez

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Yunyun Chen

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

John D. Hazle

University of Texas Health Science Center at Houston

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Vikas Kundra

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Christopher M. Walker

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Murali Ravoori

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

R. Jason Stafford

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge